Zymeworks (ZYME) Net Income towards Common Stockholders Growth (3y) (2024 - 2026)
Powered by 
Analysis
Zymeworks (ZYME) Net Income towards Common Stockholders Growth (3y) (2024 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 91.31% |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 17.25% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 37.89% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 37.44% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -38.56% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 62.15% |
| 10 | Zymeworks | 2.15 Bn | 1.88 Bn | - | 4.17% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.17% |
| Mar 31, 2026 | -21.95% |
| Dec 31, 2025 | -28.73% |
| Sep 30, 2025 | 25.73% |
| Jun 30, 2025 | 26.74% |
| Mar 31, 2025 | 32.20% |
| Dec 31, 2024 | 15.64% |
| Sep 30, 2024 | 21.02% |